Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo’s deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca’s Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
| Business Activity | PASS |
| Debt Ratio (0.36%) | FAIL |
| Cash Ratio (0.01%) | PASS |
| Receivables Ratio (0.19%) | PASS |
| Revenue Ratio (0.01%) | PASS |
| Overall | FAIL |
| Date | EPS Est. | Reported EPS | Surprise % |
|---|---|---|---|
| 2026-08-04 | -0.15 | Pending | — |
| 2026-04-30 | -1.47 | -1.28 | +13.2% |
| 2026-02-03 | 1.68 | 1.19 | -29.2% |
| 2025-10-30 | 2.06 | 2.32 | +12.8% |
| 2025-07-29 | 2.03 | 2.13 | +5.0% |
| 2025-04-24 | 2.14 | 2.22 | +4.0% |
| 2025-02-04 | 1.67 | 1.72 | +3.3% |
| 2024-10-31 | 1.57 | 1.57 | +0.0% |
| Period | Revenue | Net Income | EBITDA | Gross Profit | Op. Income | EPS |
|---|---|---|---|---|---|---|
| 2026-03-31 | $16.3B | -$4.2B | -$1.5B | $12.1B | -$3.2B | -1.72 |
| 2025-12-31 | $16.4B | $3.0B | $6.3B | $10.8B | $4.1B | 1.20 |
| 2025-09-30 | $17.3B | $5.8B | $8.2B | $13.4B | $6.6B | 2.32 |
| 2025-06-30 | $15.8B | $4.4B | $6.4B | $12.2B | $5.6B | 1.76 |
| 2025-03-31 | $15.5B | $5.1B | $7.3B | $12.1B | $5.9B | 2.01 |
| 2024-12-31 | — | — | — | — | — | — |
| Date | Name | Role | Shares | Value |
|---|---|---|---|---|
| 2026-05-01 | SMART DALTON E. III | Officer | 383 | $43.0K |
| 2026-05-01 | MARALDO DAVID R. | Officer | 552 | $61.9K |
| 2026-04-30 | SMART DALTON E. III | Officer | 1,408 | $155.3K |
| 2026-04-30 | LARSON BETTY D | Officer | 13,435 | — |
| 2026-04-29 | DELUCA RICHARD ROBERT JR. | Officer | 2,518 | — |
| 2026-04-29 | DAVIS ROBERT M | Chief Executive Officer | 13,300 | — |
| 2026-04-29 | OOSTHUIZEN JOHANNES JACOBUS | Officer | 1,377 | — |
| 2026-04-29 | CHATTOPADHYAY SANAT | Officer | 2,597 | — |
| 2026-04-29 | GUINDO CHIRFI | Officer | 1,967 | $216.4K |
| 2026-04-29 | ZACHARY JENNIFER L | General Counsel | 2,951 | — |
| Holder | Shares | Value | % Held |
|---|---|---|---|
| Blackrock Inc. | 225.8M | $27.6B | 0.1% |
| Vanguard Capital Management LLC | 161.0M | $19.7B | 0.1% |
| State Street Corporation | 119.3M | $14.6B | 0.0% |
| Wellington Management Group, LLP | 84.3M | $10.3B | 0.0% |
| Vanguard Portfolio Management LLC | 67.3M | $8.2B | 0.0% |
| Geode Capital Management, LLC | 59.6M | $7.3B | 0.0% |
| JPMORGAN CHASE & CO | 53.0M | $6.5B | 0.0% |
| Charles Schwab Investment Management, Inc. | 49.8M | $6.1B | 0.0% |
| Morgan Stanley | 47.6M | $5.8B | 0.0% |
| FMR, LLC | 44.5M | $5.4B | 0.0% |
Buy
Hold
Sell
Strong Sell
$345.8B
6.59
0.195
27
$65.8B
$49.1B
305.0%
1.83
2.77
0.0%
73,000
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| 2026-08-04 | $-0.15 | Pending | — |
| 2026-04-30 | $-1.47 | $-1.28 | +13.2% |
| 2026-02-03 | $1.68 | $1.19 | -29.2% |
| 2025-10-30 | $2.06 | $2.32 | +12.8% |
| 2025-07-29 | $2.03 | $2.13 | +5.0% |
| 2025-04-24 | $2.14 | $2.22 | +4.0% |
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($129.74, 27 analysts) | |||
| 10 | $1,113.80 | +$183.60 (16%) | 1.1R |
| 50 | $5,569.00 | +$918.00 (16%) | 1.1R |
| 100 | $11,138.00 | +$1,836.00 (16%) | 1.1R |
| To Fair Value ($193.00) | |||
| 10 | $1,113.80 | +$816.20 (73%) | 4.9R |
| 50 | $5,569.00 | +$4,081.00 (73%) | 4.9R |
| 100 | $11,138.00 | +$8,162.00 (73%) | 4.9R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
How much could this ticker lose on a bad day? These metrics measure worst-case scenarios from historical data.
Based on 10,000 simulated price paths, here is the probability of where this ticker could be in 30, 60, and 90 days.
What direction is this ticker actually moving, filtered through noise? Is it speeding up or slowing down?
Classic chart signals that institutional traders monitor. Golden Cross is bullish, Death Cross is bearish.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
These tickers tend to move together (positive) or in opposite directions (negative). Useful for portfolio diversification.
| Ticker | Correlation |
|---|---|
| XLV | 0.602 |
| PFE | 0.505 |
| AZN | 0.463 |
| AMGN | 0.447 |
| BIIB | 0.443 |
| Ticker | Correlation |
|---|---|
| NTSK | -0.221 |
| FIGR | -0.177 |
| FRMI | -0.176 |
| VIA | -0.167 |
| ATT.L | -0.165 |
Does this ticker have consistent patterns on certain days or months? Historical tendencies, not guarantees.
After this company beats earnings, does the price keep going up? Drift tracks post-earnings momentum.
How does this ticker’s recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.
Related Tickers
Similar in Healthcare
Also in TE500